Clinical Trial Search

Primary: Number of Subjects That Were Trichomonas Vaginalis (TV) Positive After Treatment With Metronidazole (MTZ) — 58; 34 Participants

Primary: TV Culture Positive Result — 11; 21 participants — p=.045

Primary: Percentage of Participants Cured of Vaginal Trichmonas — 90; 90; 88 percentage of participants

Primary: Efficacy of Monthly Periodic Presumptive Treatment (PPT) Using Metronidazole With Miconazole Intravaginal Suppositories Versus Matching Placebo Nightly for Five Nights…

Primary: Sensitivity of the OSOM Rapid Test and PCR Wet Mount Microscopy in Diagnosing Trichomonas Vaginalis in Symptomatic and Asymptomatic Women — 92; 91; 100; 100 Percentage…

Primary: Clinical Cure of Mixed Infection (BV and VVC) as Assessed by the Investigator at the Test-of-cure Visit — 31; 29; 43 Participants — p=0.030

Primary: Microbiological Cure at the TOC Visit — 59; 1 Participants

Primary: Clinical Cure as Assessed by the Investigator at the Test-of-cure Visit — 47; 25 Participants — p=0.002

Primary: Clinical Cure as Assessed by the Investigator at the Test-of-cure Visit — 47; 18 Participants — p=<0.001

Primary: Number of Patients With Bacterial Vaginosis at 3 Months — 15; 16 Participants

Primary: One-year Incidence of Chlamydial and Gonococcal Infections in Women Who Receive Screening (Every 2 Months) and Treatment for Asymptomatic Bacterial Vaginosis as Compared…

Primary: Feasibility of Integrating Point-of-care Testing (Monitoring & Evaluation Indicators) — 396; 378; 399; 216 Participants

Primary: Percentage of Participants With Presence or Absence of Symptoms 3 Days After Treatment — 67.1; 79.2; 32.9; 20.8 Percentage of Participants

Primary: Cure of Bacterial Vaginosis — 75; 73; 77 participants

Primary: Number of Participants Prescribed Appropriate Treatment — 61; 104; 58; 21 Participants — p=<.001

Primary: Community Prevalence of Trachoma and Ocular C. Trachomatis (CT) Infection at Baseline — 30.7; 30.3; 31.1; 30.5 community

Primary: p24 Antigen Production in Tissue

Primary: Percentage of Study Successes in the EVO100 and Placebo Treatment Groups — 684; 696 Participants

Primary: Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Nausea — 3; 4; 0; 4 Participants

Primary: The i) Percent Sensitivity and ii) Percent Specificity of Click Device for Detection of Chlamydia Trachomatis (CT) in Self-collected Vaginal Specimens as Compared to PIS…

Primary: Number of Participants With Bacterial Vaginosis Recurrence — 8 Participants

Primary: Clinical Treatment Efficacy Assessed by the Investigator After Thorough Gynaecological Examination and Patient's Interview at End of Treatment Visit — 275; 268; 27; 41…

Primary: Recurrent Trichiasis in Tetracycline and Azithromycin Groups — 45; 62 Participants — p=.047

Primary: HPV Incidence Rates, Expressed as Incident Infections/1000 Infection-months at Risk. These Were Calculated Separately for Females and Males Across the Four Vaccine…

Primary: Number of Participants Who Were Cured — 120; 130 Participants — p=<0.001

Primary: The Competitive Index of the Mutant Compared to Wild Type Proportion of Organisms With the Predicted Competitive Advantage Recovered From Urine and/or Urethral Swab…

Primary: Proportion of Participants With Recurrent Bacterial Vaginosis (RBV) by Visit 4, as Defined by Presence of at Least 3 Amsel Criteria — 0.581; 0.697 proportion of…

Primary: The Proportion of Participants That Become Infected With Individual N. Gonorrhoeae Strains in Non-competitive Infections — 0.80; 1.00 proportion of participants — p=1.000

Primary: Number of Female Partners Whose Male Partners Received Metronidazole Versus Females Whose Male Partners Did Not Receive Metrodiazole With Recurrence of BV in the Female…

Primary: Number of Participants With the Same Gynaecological Conditions at the End of Treatment Visit — 13 Participants